Document is current
Any future updates will be listed below
-
Authors
Skjellerudsveen, Berit Mære
Skoie, Inger Marie
Dalen, Ingvild
Grimstad, Tore
Omdal, Roald https://orcid.org/0000-0002-6051-4658
-
Funding
Funding for this research was provided by:
Stavanger Universitetssjukehus
University of Bergen
- License Information
-
More Information
Article History
Accepted: 3 May 2023
First Online: 23 May 2023
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: IMS has served as a speaker for AbbVie and Pfizer and advisory board member for Novartis, Eli-Lilly, Janssen, AbbVie, and Pfizer. TG has served as a speaker for Ferring Pharmaceuticals, Takeda, and advisory board member for Takeda, Janssen-Cilag, and Tillotts Pharma. RO has served as a speaker for Swedish Orphan Biovitrum and Novartis Norway. BMS and ID declare that they have no conflicts of interest.
: All data used to perform this meta-analysis are publicly available. There are no disclosures to report.
: Open access funding provided by University of Bergen (incl Haukeland University Hospital). This article was supported by a grant from Stavanger University Hospital.
: BMS was responsible for data collection, performing the analysis, and writing the paper. IMS was responsible for data collection and writing the paper. ID was responsible for performing the analysis and writing the paper. TG was responsible for writing the paper. RO conceived the study and wrote the paper.
